Pfizer expands ‘An Accord for a Healthier World’ program to bridge global health equity gap
An expansion of Pfizer’s not-for-profit health equity program will offer up to 500 patented and off-patent products to 45 lower-income countries, building on their initial offering of patented medicines and vaccines in the US and EU.
Pharmaceutical giant Pfizer has announced a major expansion of the program ‘An Accord for a Healthier World’, an initiative aimed at providing medicines and vaccines to lower-income countries on a not-for-profit basis. The expansion now includes their full portfolio of approximately 500 therapeutics and vaccines.
‘An Accord for a Healthier World’ was launched in May 2022 as part of a commitment from Pfizer to provide access to its full portfolio of patented medicines and vaccines in the US and EU. The program also aimed to reach 1.2 billion people in 45 countries classed as lower-income, targeting the treatment of some cancers, infectious diseases, and inflammatory diseases. In November, Pfizer deployed the first Global Health Team to Rwanda to identify opportunities for long-term supply chain optimization. Additional collaborations with the Ministries of Health in Malawi, Ghana, and Senegal aim to better understand the healthcare needs for each community and discover opportunities for strengthening the existing healthcare systems.
Chairman and CEO of Pfizer Albert Bourla commented: “We launched the Accord to help reduce the glaring health equity gap that exists in our world. Our hope is to empower country governments and co-create solutions with them and other multi-sector partners to break down many of the system-level barriers to better health.”
The expansion of this program will now include off-patent products, increasing the number of available treatments from 23 to nearly 500 therapeutics and vaccines for the treatment and prevention of infectious and non-communicable diseases prevalent in lower-income countries. These treatments include chemotherapies, oral cancer medications, and a wide range of antibiotics to address a rise in prevalence, mortality, and costs incurred by antimicrobial resistance. The program is projected to prevent 1.5 million deaths associated with bacterial infections in community health clinics and hospitals.
Commenting on the need to close the health equity gap, Bourla added: “In the months since the Accord’s launch, we have heard resoundingly from these leaders that access to a broader and more immediate scope of consistent, high-quality products is needed for meaningful and sustainable transformation. We believe this expansion of our product offering, combined with continued efforts to help address the barriers that limit or prevent access, will help us to achieve and even expedite our vision of a world where all people have access to the medicines and vaccines they need to live longer and healthier lives.”
Sources
Related News
-
News How to disrupt an industry as big as pharma for the better?
In this interview, hear from Matthew Wise, Head of Data at CCD Partners, on the companies they've been looking into that are offering new and interesting perspectives that have the potential to shake up the pharmaceutical industry, and how they'... -
News CPHI Pharma Awards 2024: Meet the winners from the CPHI Celebration
This year we had a lot to celebrate, the 35th Anniversary of CPHI, and our esteemed award winners, of which we included two additional categories this year, the Future Leader award, and Woman of the Year award. -
News CPHI Milan 2024 - From the Floor
Milan and CPHI welcome you to 2024 CPHI Milan! As we celebrate the 35th edition of our flagship CPHI show, editors Vivian Xie and Lucy Chard bring you the latest from the show floor, conference sessions, and innovative solutions from all exhibitors, at... -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News A Day in the Life of a Global CDMO Chapter Lead – Manufacturing
The 'Day in the Life of' series has covered many aspects of the pharmaceutical pipeline, including R&D and procurement, now we're taking a look at manufacturing from a global CDMO perspective. -
News Eisai Alzheimer’s drug authorised in UK but still faces obstacles
In partnership with BioArctic AB, pharmaceutical company Eisai has been granted Marketing Authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) for its Alzheimer’s disease drug product Leqembi. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance